| Value | ₹99.05 Cr |
|---|---|
| Execution period | 18 months |
BSE filing, NSE: VIKASLIFE. Summary written from the filing by ALFA Finder's alert engine.
Vikas Lifecare Ltd: key numbers
- Share price
- ₹1.11
- Market cap
- ₹206.2 Cr
- Revenue (annual)
- ₹499.4 Cr
- Net profit (annual)
- ₹18.41 Cr
- P/E (TTM)
- -1.9×Sector 45.0×
- Promoter holding
- 14.20%+0.00% QoQ
- FII holding
- 0.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vikas Lifecare Ltd
All →Vikas Lifecare Other Announcement
Vikas Lifecare Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.
Vikas Lifecare Annual General Meeting
Vikas Lifecare obtained ROC approval to extend its FY26 AGM by 2 months and 28 days. The new AGM date will be communicated once finalised by the Board.
Vikas Lifecare Other Announcement
Vikas Lifecare Limited has applied to the Registrar of Companies for an extension of time to convene its Annual General Meeting for FY 2025-26.
Vikas Lifecare ED Probe / Tax Survey
Vikas Lifecare promoter Vikas Garg was taken into custody by the Directorate of Enforcement. The company states there is currently no material impact on business operations.
Vikas Lifecare Board Meeting Outcome
Vikas Lifecare approved its audited standalone and consolidated financial results for FY26. The auditor's report highlights qualified opinions and various emphasis of matter items.
Vikas Lifecare Q4 FY26 Results: Turns Profitable, Net Profit ₹41.6 Cr
Vikas Lifecare Ltd reported revenue from operations of ₹168.6 Cr (+24.7% YoY) and net profit of ₹41.6 Cr for Q4 FY26.
- Key figure
- Net profit ₹41.6 Cr
Other fund raise announcements
All →Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.